| Document |
Document Title |
|
WO/2011/141004A1 |
A cefodizime sodium hydrate, preparation method and uses thereof are disclosed. The said cefodizime sodium hydrate has better storage stability, and is applicable to pruduce medicaments for treating or preventing human or animals disease...
|
|
WO/2011/136268A1 |
Provided is a cephem compound represented by the following formula, having a broad antibacterial spectrum, and exhibiting strong antibacterial activity particularly with respect to β-lactamase producing gram-negative bacteria. Also prov...
|
|
WO/2011/125967A1 |
Disclosed is a compound represented by formula (I) (wherein X represents -N=, -CH= or the like; W represents -CH2- or the like; U represents -S- or the like; R1 and R2 each independently represents a hydrogen atom, a halogen atom, an opt...
|
|
WO/2011/125966A1 |
Disclosed are a compound shown by formula (I), an ester thereof, or a protected product thereof in which an amino group located on the ring in the 7-position side chain is protected, a pharmaceutically acceptable salt of the compound, es...
|
|
WO/2011/121389A1 |
A process for preparation of cefepime dihydrochloride monohydrate is provided. The process comprises condensing 7-amino-3-[(l -methyl- 1 -pyrrolidino)methyl]-3-cephem-4-carboxylate monohydrochloride dihydrate and 2-mercaptobenzothiazolyl...
|
|
WO/2011/113361A1 |
Disclosed are a ceftizoxime sodium crystalline hydrate, preparation methods and uses thereof. The ceftizoxime sodium crystalline hydrate has high storage stability, and is suitable for preparing medicaments for treating or preventing dis...
|
|
WO/2011/103686A1 |
The present invention relates to cephalosporin derivatives having β- lactamase inhibitory activity. The compounds are useful in preventing or treating bacterial resistance to an antibiotic, e.g. a β-lactam antibiotic. Disclosed herein ...
|
|
WO/2011/093294A1 |
Provided is a process by which an objective cephalosporin derivative having a high Z-isomer content or an alkali metal salt thereof can be prepared via simple steps with industrial advantages. A process for the preparation of a cephalosp...
|
|
WO/2011/078819A1 |
Present invention relates to pharmaceutically acceptable salts of cefdinir, specifically to primary, secondary and tertiary amine salts of cefdinir, preperation methods and pharmaceutical compositions comprising them.
|
|
WO/2011/077217A1 |
The present invention relates to the preparation of cefpodoxime acid of formula (I) using alcoholic solvent in the presence or absence of water in a very safe, simple, economical, user-friendly and in an industrially viable manner.
|
|
WO/2011/042776A1 |
A process for the preparation of cefotaxime acid of formula (IV) and pharmaceutically acceptable salt thereof, such as cefotaxime sodium of formula (I) is provided, which comprises condensing the compound of formula (II) with the compoun...
|
|
WO/2011/042775A1 |
Cefotaxime acid of formula (I) is prepared by using a kind of alcohol as the single solvent in presence of a base.
|
|
WO/2011/012965A1 |
The preparation of ceftriaxone disodium hemiheptahydrate of formula (I) using alcoholic solvent in a very safe, simple, economical, user-friendly and in an industrially viable manner is provided.
|
|
WO/2011/009827A1 |
Disclosed is a process for the production of particles of a cefquinome acid addition salt, preferably cefquinome sulfate particles, by precipitation of cefquinome acid addition salt, preferably the sulfate, from a cefquinome betaine solu...
|
|
WO/2010/136423A1 |
The invention relates to a method for the production of organic compounds, in particular sodium (6R,7R)-7-[(Z)-2-(5-amino-[1,2,4]thiadiazole-3-yl)-2-hydroxy
imino-acetylamino]-8-oxo-3-[(E)-(R)-1'-(5-methyl-2-oxo-[1,3]
-dioxol-4-ylmethoxy...
|
|
WO/2010/136422A1 |
The invention relates to a method for the production of organic compounds, in particular sodium (6R,7R)-7-[(Z)-2-(5-amino-[1,2,4]thiadiazole-3-yl)-2-hydroxy
imino-acetylamino]-8-oxo-3-[(E)-(R)-1'-(5-methyl-2-oxo-[1,3]
-dioxol-4-ylmethoxy...
|
|
WO/2010/075765A9 |
The invention provides an acid double salt of cefdinir. The acid double salt is obtained by reacting cefdinir with acid and alkali metal element or ammonium (including ammonia) compound or with acid salt. The cefdinir sulfate double salt...
|
|
WO/2010/097675A1 |
The present invention relates to an improved process for the preparation of cefpodoxime proxetil of formula (I) from cefpodoxime acid (II) by reacting 1 -iodoethyl isopropyl carbonate (III) in an aprotic solvent in presence of a mixture ...
|
|
WO/2010/089729A1 |
The present invention relates to processes for the preparation of cefozopran of Formula (I), its salts and polymorphic forms thereof.
|
|
WO/2010/083725A1 |
Compounds of formula I, pharmaceutically acceptable salts, esters, isomers or solvates thereof, wherein R1 and R2 are independently hydrogen, C1-6 alkyl or amino- protecting group; X is N and the like; R3 is H and the like；ring B is a ...
|
|
WO/2010/082108A1 |
An improved process for the preparation of 7-phenylacetamido-3-vinyl cephalosporanic acid-p-methoxybenzyl ester of formula (I), which is a key intermediate of cephalosporin antibiotics and is extremely useful in their synthesis, is provi...
|
|
WO/2010/072672A1 |
A compound of formula (I) in a crystalline form, which has a X-ray diffraction pattern comprising, when measured using Cu- Kα1 radiation, a diffraction line, having a relative intensity (rl) of 100 percent at about 11.6, 12.9, 14.7, 22....
|
|
WO/2010/050468A1 |
Disclosed is a cephem compound represented by formula (I) [wherein X represents N, CH, or C-Cl; T represents S, or the like; A and G independently represent a lower alkylene, or the like; B represents a single bond, or the like; D repres...
|
|
WO/2010/030858A1 |
The present invention discloses compounds of formula (I), or its β-L enantiomer, or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, solvate, prodrug, or combination thereof: Formula (I) which inhibit, preventing or tr...
|
|
WO/2010/020871A2 |
The present invention relates to novel polymorphs of Ceftiofur sodium as a crystalline product. The present invention also provides a process for the preparation of novel polymorphs of crystalline Ceftiofur sodium of formula (I).
|
|
WO/2009/149657A1 |
A macro-porous adsorption resin specially used for extracting cephalosporin C and a preparation method for the macro-porous adsorption resin. The specific surface of the adsorption resin is ranging from 1000 -2000 m2/g and the pore volum...
|
|
WO/2009/137062A2 |
The present invention provides photosensitizer compounds for use in detecting beta- lactamase activity. Methods and kits that utilize the photosensitizer compounds of the invention for the detection of, quantitation of, and classificatio...
|
|
WO/2009/129662A1 |
A process for the preparation of 7-phenylacetamido-3-chloromethyl-3-cephem-4-carboxylic acid p-methoxybenzyl ester(GCLE), comprises the steps of: reacting penicillin G potassium salt with 4-methoxybenzyl chloride to obtain penicillin G 4...
|
|
WO/2009/127623A1 |
A solid DMSO solvate of a compound of formula (I) is described, which is a useful intermediate for preparing the broad spectrum antibiotics Ceftobiprole and Ceftobiprole Medocaril.
|
|
WO/2009/016170A1 |
The present invention relates to a process for the silylation of a β-lactam compound in an organic solvent comprising one or more silylating agents characterized in that the process is carried out in the presence of an effective amount ...
|
|
WO/2009/016171A1 |
The present invention relates to a composition comprising at least 90 wt% of a β-lactam compound characterized in that it contains between 0.02 and 5 wt% ammonium chloride and/or a corresponding amount of the HCI salt of an organic amine.
|
|
WO/2009/004463A1 |
The present invention provides a process for the preparation of the compound of formula (I) wherein HX represents HI, HCl, H2SO4 and the like. The compound of formula (I) is an important intermediate in the preparation of Cefepime.
|
|
WO/2008/155615A2 |
The present invention provides a process for the preparation of the compound of formula (I) and its salt and esters. More particularly, this present invention relates to an improved process for the preparation Cefcapene of formula (I) an...
|
|
WO/2008/132574A1 |
The present invention relates to a process for the purification of cefuroxime acid {(6R,7R)-3-carbamoyloxymethyl-7-[(Z)-2-(fur-2-yl)-2-methoxy-
iminoacetamido] ceph-3-em-4-carboxylic acid} of formula (I).
|
|
WO/2008/056221A1 |
The present invention relates to novel crystalline form of cephalosporin sulfate of the following formula and provides a process for preparing the same.
|
|
WO/2008/056221A2 |
The present invention relates to novel crystalline form of cephalosporin sulfate of the following formula and provides a process for preparing the same.
|
|
WO/2008/047376A1 |
An improved one pot process for the preparation of Ceftiofur of the formula (I) or its salt, without isolating the intermediate compound.
|
|
WO/2008/041100A1 |
Abstract The present invention more particularly relates to a process for the preparation of cephalosporin antibiotics of the Formula (I) wherein R1 represents hydrogen, trityl, alkyl like CH3, CRaRbCOORc where Ra and Rb independently re...
|
|
WO/2008/010042A2 |
The present invention provides a process for the preparation of the compound of formula (I) wherein X represents iodo or chloro. The compound of formula (I) is an important intermediate in the preparation of Cefepime or its pharmaceutica...
|
|
WO/2008/010043A2 |
The present invention provides an improved process for the preparation of the compound of formula (I) in pure form.
|
|
WO/2008/002245A2 |
The present invention relates to a compound of formula (I) as a free base or a pharmaceutically acceptable salt thereof. The present invention also relates to pharmaceutical formulations containing said compound and to the use of said co...
|
|
WO2007105253B1 |
There is described a process for the preparation of carboxy-protected 7ß-amino-7a-methoxy-(l-oxa- or l-thia-)3-(l-substituted-lH-tetrazol-5-yl)thiomethyl-3- cephem-4-carboxylic acid. Said process comprises (a) reacting a carboxy- protec...
|
|
WO/2007/134987A1 |
The present invention relates to a process for the preparation of cefadroxil in crystal form, comprising a) adding an aqueous solution of cefadroxil to a crystallisation vessel and a titrant to keep a pH in the crystallisation vessel of ...
|
|
WO/2007/121933A1 |
The invention relates to a novel crystalline modification of cefuroximaxetil (ε modification), to pharmaceutical preparations comprising this modification, and to their use.
|
|
WO/2007/122628A1 |
The present invention provides an improved process that is suitable for large-scale preparation of pure cefotetan disodium (1b) that comprises of one pot process for deprotection of both tert-butyl and benzhydryl ester groups of cefoteta...
|
|
WO/2007/119511A1 |
The present invention provides a compound of the formula [I]: wherein R1 is lower alkyl, etc. and R2 is hydrogen, etc., or R1 and R2 are bonded together to form lower alkylene; R3 is a group represented by wherein R6 and R7 are independe...
|
|
WO/2007/096740A2 |
The present invention relates to novel compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and...
|
|
WO/2007/096419A1 |
The present invention relates to a cephalosporin-producing microorganism characterized in that it has been transformed with a heterologous CefT gene and whereby the ratio of the cephalosporin production capacity of the microorganism tran...
|
|
WO/2007/056918A1 |
Sodium cefazolin pentahydrate crystal and its assembly preparation method were disclosed in the present invention. There are five molecules of water within one molecule of the crystalline structure of sodium cefazolin pentahydrate. It be...
|
|
WO/2007/054777A1 |
The present invention relates to the process for the depletion of E isomer of Cefditoren sodium of formula (I).
|
